{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ryan CJ"],"funding":["NCI NIH HHS"],"pagination":["2791-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5569674"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(22)"],"pubmed_abstract":["Purpose
In the phase III study COU-AA-301, abiraterone acetate (AA) plus prednisone (P) prolonged overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel administration. In this article, we investigate the relationship between baseline serum androgen (SA) levels and OS.Patients and methods
COU-AA-301 is a randomized, double-blind study of AA (1,000 mg every day) plus P (5 mg by mouth twice daily; n = 797) versus P alone (n = 398). Randomization was stratified by Eastern Cooperative Oncology Group performance status (0 to 1 v 2), pain (Brief Pain Inventory-Short Form over past 24 hours: 4 to 10, present; v 0 to 3, absent), prior chemotherapy (1 v 2), and progression (prostate-specific antigen v radiographic). Association"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial."],"pmcid":["PMC5569674"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Ryan CJ","Grant RP","Li J","Haqq CM","Molina A","de Bono JS","Scher HI","Kheoh T","Small EJ"],"additional_accession":[]},"is_claimable":false,"name":"Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial.","description":"Purpose
In the phase III study COU-AA-301, abiraterone acetate (AA) plus prednisone (P) prolonged overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel administration. In this article, we investigate the relationship between baseline serum androgen (SA) levels and OS.Patients and methods
COU-AA-301 is a randomized, double-blind study of AA (1,000 mg every day) plus P (5 mg by mouth twice daily; n = 797) versus P alone (n = 398). Randomization was stratified by Eastern Cooperative Oncology Group performance status (0 to 1 v 2), pain (Brief Pain Inventory-Short Form over past 24 hours: 4 to 10, present; v 0 to 3, absent), prior chemotherapy (1 v 2), and progression (prostate-specific antigen v radiographic). Association","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Aug","modification":"2025-04-04T09:53:52.442Z","creation":"2019-03-27T02:54:24Z"},"accession":"S-EPMC5569674","cross_references":{"pubmed":["23816964"],"doi":["10.1200/jco.2012.45.4595","10.1200/JCO.2012.45.4595"]}}